1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Relyvrio’s Failure Sparks NeuroSense ALS Development Changes

 
• By Derrick Gingery

NeuroSense plans to adjust its upcoming clinical trial to avoid the fate of Amylyx’s ALS candidate, which was recently withdrawn from the market due to a lack of efficacy.

neuron-degeneration
NeuroSense is planning a Phase III study for its ALS candidate PrimeC. • Source: Shutterstock

The saga of the ALS treatment Relyvrio may be generating ripple effects across the disease landscape.

Key Takeaways

  • NeuroSense is adjusting its Phase III trial design in part because of Relyvrio's failure.

Alon Ben-Noon, CEO of NeuroSense Therapeutics Ltd., which is developing PrimeC as an amyotrophic lateral sclerosis treatment, said the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

UK HRA Sets Targets For Digital Overhaul, Trial Transparency And Trust

 
• By Vibha Sharma

The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.

Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility

 
• By Bridget Silverman

Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.

Organ-On-A-Chip: Upcoming US FDA Guidance Could Help Flesh Out ‘Roadmap’

 
• By Michael McCaughan

The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.